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Summary
Background:  Low  levels  of  vitamin  D  may  play  a  role  in  psychiatric  disorders,  as  cross-sectional
studies show  an  association  between  vitamin  D  deﬁciency  and  depression,  schizophrenia  and
psychotic  symptoms.  The  underlying  mechanisms  are  not  well  understood,  although  vitamin  D
is known  to  inﬂuence  the  immune  system  to  promote  a  T  helper  (Th)-2  phenotype.  At  the  same
time, increased  inﬂammation  might  be  of  importance  in  the  pathophysiology  of  depression  and
suicide. We  therefore  hypothesized  that  suicidal  patients  would  be  deﬁcient  in  vitamin  D,  which
could be  responsible  for  the  inﬂammatory  changes  observed  in  these  patients.
Methods: We  compared  vitamin  D  levels  in  suicide  attempters  (n  =  59),  non-suicidal  depressed
patients  (n  =  17)  and  healthy  controls  (n  =  14).  Subjects  were  diagnosed  according  to  the  Diag-
nostic and  Statistical  Manual  of  Mental  Disorders,  4th  edition,  and  went  through  a  structured
interview by  a  specialist  in  psychiatry.  25(OH)D2 and  25(OH)D3 were  measured  in  plasma  using
liquid-chromatography—mass-spectrometry  (LC—MS).  We  further  explored  vitamin  D’s  associa-
tion with  plasma  IL-1, IL-6  and  TNF-.
Results:  Suicide  attempters  had  signiﬁcantly  lower  mean  levels  of  vitamin  D  than  depressed
non-suicidal  patients  and  healthy  controls.  58  percent  of  the  suicide  attempters  were  vitamin
D deﬁcient  according  to  clinical  standard.  Moreover,  there  was  a  signiﬁcant  negative  association
between  vitamin  D  and  pro-inﬂammatory  cytokines  in  the  psychiatric  patients.  Low  vitamin  D
levels were  associated  with  higher  levels  of  the  inﬂammatory  cytokines  IL-6  and  IL-1  in  the
blood.
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Vitamin  D  deﬁciency  in  suicide  attempters  
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1. Introduction
The  etiology  of  suicidal  behavior  is  likely  to  be  multi-
factorial,  with  genetic,  environmental  and  psychological
factors  involved.  Personality  disorders  (especially  border-
line  personality  disorder)  and  major  depressive  disorder  are
established  risk  factors  for  suicidal  behavior.  Among  the
underlying  biological  changes,  accumulating  studies  indicate
that  a  dysregulated  immune  system  could  be  a  contributing
factor  to  depression,  and  possibly  speciﬁcally  to  suicidal-
ity  (Muller,  2014).  Direct  evidence  of  causality  comes  both
from  animal  models,  where  induction  of  peripheral  inﬂam-
mation  is  known  to  lead  to  depressive  changes  (Bay-Richter
et  al.,  2011),  and  from  so  called  cytokine-induced  depres-
sion  in  humans  (Capuron  et  al.,  2002),  where  treatment
with  interferons  (IFN)  of  patients  with  hepatitis  increases
the  risk  for  development  of  both  depression  and  suicidal-
ity  (Wichers  and  Maes,  2002).  Post-mortem  studies  indicate
that,  irrespective  of  their  primary  psychiatric  diagnosis,
patients  who  die  from  suicide  exhibit  an  increased  level
of  microgliosis  as  a  sign  of  neuroinﬂammation  (Steiner
et  al.,  2008).  Other  studies  show  elevated  cytokine  mRNA
expression  in  the  brains  of  suicide  victims  (Pandey  et  al.,
2012;  Tonelli  et  al.,  2008).  We  previously  demonstrated
that  patients  who  attempted  suicide  have  elevated  levels
of  the  pro-inﬂammatory  cytokine  interleukin  (IL)-6  in  the
cerebrospinal  ﬂuid  (Lindqvist  et  al.,  2009),  and  that  sui-
cidal  patients  have  more  pronounced  inﬂammation  in  the
blood  than  non-suicidal  patients  with  depression  (Janelidze
et  al.,  2011).  Conﬁrming  these  results,  O’Donovan  et  al.
(2013)  recently  showed  that  suicidal  ideation  in  depressive
patients  is  speciﬁcally  coupled  to  increased  inﬂammation  in
the  blood.
The  pattern  of  inﬂammation  in  plasma  of  depressive
and  suicidal  patients  involves  common  pro-inﬂammatory
cytokines  such  as  IL-6,  tumor  necrosis  factor  (TNF)-, and
also  the  acute  phase  reactant  C-reactive  protein  (CRP)
(Dowlati  et  al.,  2010).  In  most  cases  the  origin  of  the
observed  low-grade  inﬂammation  is  unknown.  It  could
theoretically  stem  from  many  different  sources,  such  as
infectious  agents,  autoimmune  reactions  or  stress  (Zhang
et  al.,  2012b;  Liu  et  al.,  2013).  Low  levels  of  vitamin
D  have  also  been  suggested  to  contribute  to  different
psychiatric  disorders  (Kjaergaard  et  al.,  2011;  Belvederi
Murri  et  al.,  2013).  Interestingly,  vitamin  D  exerts  profound
immuno-modulating  effects  (Borges  et  al.,  2011).  Several
cross-sectional  studies  have  shown  a  relation  between  low
levels  of  vitamin  D  and  more  severe  depressive  symptoms
(Milaneschi  et  al.,  2014)  and  there  is  an  over-representation
of  vitamin  D  deﬁciency  among  patients  with  psychiatric  ill-
nesses  (McCue  et  al.,  2012).  Two  recent  prospective  studies
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rs  in  our  study  were  deﬁcient  in  vitamin  D.  Our  data  also  sug-
uld  be  a  contributing  factor  to  the  elevated  pro-inﬂammatory
suicidal  patients.  We  propose  that  routine  clinical  testing  of
al  in  patients  with  suicidal  symptoms,  with  subsequent  supple-
 deﬁcient.
y  Elsevier  Ltd.  This  is  an  open  access  article  under  the  CC
commons.org/licenses/by-nc-nd/3.0/).
id  indeed  ﬁnd  that  low  vitamin  D  levels  increase  the  risk
or  depression  (Bertone-Johnson  et  al.,  2011;  Milaneschi
t  al.,  2010).  Also,  a  randomized  double  blind  controlled
rial  showed  that  supplementation  with  vitamin  D  for  one
ear  had  beneﬁcial  effects  on  depressive  symptoms  in  over-
eight  subjects  (Jorde  et  al.,  2008).  However,  the  ﬁndings
n  the  ﬁeld  are  not  consistent,  which  partly  might  be  due  to
ethodological  differences.
The  relationship  of  vitamin  D  deﬁciency  and  suicidal-
ty  has  been  addressed  in  a  small  number  of  studies  to
ate  (Umhau  et  al.,  2013;  Tariq  et  al.,  2011).  Umhau  et  al.
2013)  found  that  low  vitamin  D  status  is  common  in  active
uty  service  members,  and  the  lowest  levels  were  asso-
iated  with  an  increased  suicide  risk.  Tariq  et  al.  (2011)
ypothesized  that  vitamin  D  deﬁciency  could  be  associ-
ted  with  increased  risk  of  completed  suicides  and  found
n  association  of  vitamin  D  deﬁciency  with  multiple  suicide
isk  factors,  such  as  chronic  medical  illnesses  (autoimmune
isorders,  ﬁbromyalgia  and  cancer),  mood  and  anxiety  disor-
ers  and  schizophrenia.  A  seasonal  pattern  of  suicides  and
ttempts,  with  a  peak  incidence  occurring  in  spring/early
ummer  for  men  and  a  bi-modal  peak  in  spring/early  sum-
er  and  autumn  for  women,  is  a  well-known  phenomenon
n  countries  with  a temperate  climate  (Christodoulou  et  al.,
012).  These  peaks  cohere  reasonably  well  with  the  seasonal
ariations  of  vitamin  D  levels  in  people  living  in  respective
ountries  (Rosecrans  and  Dohnal,  2014).  For  personality  dis-
rders,  there  is  a  lack  of  studies  investigating  the  impact
f  vitamin  D.  One  recent  study  did  explore  the  relationship
etween  vitamin  D  and  basic  personality  traits,  and  indi-
ated  that  vitamin  D  might  promote  an  extrovert  and  open
ehavior.  However,  individuals  with  manifest  Axis-I  or  Axis-II
isorders  were  excluded  (Ubbenhorst  et  al.,  2011).
The  effects  of  vitamin  D  on  the  immune  system  include  a
hift  in  the  T  helper  (Th)-balance  towards  a  Th2-phenotype,
hich  in  short  can  be  said  to  result  in  a  less  pro-inﬂammatory
tate  (van  Etten  and  Mathieu,  2005).  Since  the  immune
ysregulation  observed  in  depressed  patients  and  suicide
ttempters  include  elevated  levels  of  pro-inﬂammatory
ytokines,  we  hypothesized  that  these  patients  suffer  from
n  underlying  vitamin  D  deﬁciency.  We  therefore  compared
he  vitamin  D  levels  between  a  group  of  suicide  attempters,
 group  of  non-suicidal  depressed  patients  and  a  group  of
ealthy  controls  and  explored  the  relation  between  vitamin
 and  inﬂammatory  cytokines  in  blood.  We  have  previ-
usly  established  that  the  suicide  attempters  in  this  cohort
ave  increased  levels  of  IL-6  and  TNF- (Janelidze  et  al.,
011).  In  addition,  we  explored  the  vitamin  D  blood  lev-
ls  in  the  main  groups  of  psychiatric  diagnoses  (Axis-I  and
xis-II)  as  well  as  its’  relation  to  speciﬁc  aspects  of  suicidal
ehavior.
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Table  1  Characteristics  of  the  study  participants  regarding  medical  treatment  and  somatic  conditions.
Variable  Suicide  attempters  (n  =  59)  Non-suicidal
depressed  patients
(n  =  17)
Healthy  controls
(n  =  14)
Medication  (n) SNRI  (11)
SSRI  (10)
Neuroleptics  +  SSRI  (6)
Anti-epileptics  (6)
Anti-epileptics  +  other  (4)
Lithium  (3)
Other  combinations  (9)
Somatic  illnessa (n) bEndocrine-nutritional  and  metabolic
diseases  (10)
cEndocrine-
nutritional  and
metabolic  diseases
(2)
dNervous  system  diseases  (6) eNervous  system
diseases  (2)
Eye diseases  (1)
Ear  diseases  (1)
Circulatory  system  diseases  (4)
Respiratory  tract  diseases  (1)  Respiratory  tract
diseases  (1)
Respiratory  tract
diseases  (1)
Digestive system  diseases  (3)  Digestive  system
diseases  (1)
Skin diseases  (1) Skin  diseases  (1)
Musculoskeletal  diseases  (6)
fPain  conditions  (3)
gAllergy  (2) hAllergy  (1) iAllergy  (3)
a 10 of the suicide attempters, 1 of the non-suicidal depressed patients and 1 of the healthy controls had two or more somatic illnesses.
b 7 of the suicide attempters had an endocrine condition; 3 had diabetes and 4 had a thyroid disease.
c 1 of the non-suicidal depressed patients had an endocrine condition; Polycystic Ovarian Syndrome (PCO).
d Multiple Sclerosis (1), sequelae intoxication (1), migraine (2), ﬁbromyalgia (1), neuropathy (1).
e Migraine (1), ﬁbromyalgia (1).
f Post. op. fractures after suicide attempt (1), oriﬁce of the stomach (1), pain NOS (1).
g Pollen allergics (1), nickel allergy (1).
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i Cat, horse, pollen allergics, hard fruit (1), furred animal, hay 
. Subjects and methods
his  study  was  approved  by  the  Ethical  Review  Board  for
uman  studies,  Lund/Malmö,  Sweden  (479/2006  and  LU  82-
1).  All  patients  gave  their  written  informed  consent  before
nrollment.  The  research  was  performed  according  to  the
rinciples  expressed  in  the  declaration  of  Helsinki.
.1.  Subjects
etails  about  medication  and  somatic  illness  of  the  study
articipants  are  given  in  Table  1.
.1.1.  Suicide  attempters
 total  of  59  patients  (25  men  and  34  women)  were
nrolled  on  admission  to  Lund  University  Hospital  after  a
uicide  attempt.  Mean  age  of  the  patients  was  38  years
range  18—73,  SD  14  years)  and  mean  body  mass  index
BMI)  26  kg/m2 (range  17-34,  SD  4  kg/m2).  The  patients
ere  diagnosed  according  to  the  DSM-IV  as:  schizoaffective
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isorder  (n  =  2),  psychotic  disorder  NOS  (n  =  1),  major
epressive  disorder  (n  =  10),  bipolar  I  disorder  (n  =  3),  bipolar
I  disorder  (n  =  12),  anxiety  disorder  NOS  (n  =  4),  generalized
nxiety  disorder  (n  =  1),  dysthymic  disorder  (n  =  4),  alcohol
ependence  (n  =  6),  substance  dependence  (n  = 2),  adjust-
ent  disorder  (n  =  7),  adjustment  disorder  with  depressed
ood  (n  = 3)  and  depressive  disorder  NOS  (n  =  3).  29  of  the
uicide-attempters  had  an  Axis-II  disorder,  49  were  treated
ith  psychotropic  drugs  at  the  time  for  sample  collection
nd  25  of  the  suicidal  patients  had  a  somatic  diagnosis
Table  1).
.1.2.  Control  group  I:  Non-suicidal  depressed  patients
7  non-suicidal  patients  (9  men  and  8  women)  with  major
epressive  disorder  were  recruited  from  the  Psychiatric
linic,  Lund  University  Hospital.  Mean  age  of  the  patients
ere  35  years  (range  22—54,  SD  11  years)  and  mean  BMI
5  kg/m2 (range  18—54,  SD  8  kg/m2).  The  severity  of  the
epression  among  the  patients  was  a  median  MADRS  total
core  of  25  (IQR:  23—31.5),  which  equals  moderate  depres-
ion  severity.  The  non-suicidal  depressed  patients  were
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not  treated  with  any  psychotropic  drugs  for  at  least  one
month  before  sample  collection.  Seven  of  the  non-suicidal
depressed  patients  had  a  somatic  diagnosis  (Table  1).
2.1.3.  Control  group  II:  Healthy  subjects
14  healthy  controls  subjects  (7  men  and  7  women)  without
any  previous  or  ongoing  psychiatric  condition  were  ran-
domly  selected  from  the  municipal  population  register  in
Lund.  Mean  age  of  the  healthy  subjects  was  33  years  (range
23—55,  SD  11  years)  and  mean  BMI  23  kg/m2 (range  20—28,
SD  3  kg/m2).  None  of  the  healthy  subjects  were  treated  with
psychotropic  drugs.  Three  participants  in  the  control  group
had  a  somatic  condition  (Table  1).
2.2.  Clinical  evaluation
All  subjects  went  through  a  structured  interview  by  a  spe-
cialist  in  psychiatry  and  were  diagnosed  according  to  the
Diagnostic  and  Statistical  Manual  of  Mental  Disorders  4th
edition  (DSM  IV)  and  the  Structured  Clinical  Interview  for
DSM  IV  (SCID)  I  and  II  (American  Psychiatric  Association,
1994).  A  suicide  attempt  was  deﬁned  as:  ‘Those  situations  in
which  a  person  has  performed  an  actually  or  seemingly  life
threatening  behavior  with  the  intent  of  jeopardizing  his/her
life  or  to  give  the  appearance  of  such  intent,  but  which
has  not  resulted  in  death’  (Beck  et  al.,  1972).  The  suicide
attempts  were  classiﬁed  into  violent  or  non-violent  based
on  the  following  criteria,  as  previously  deﬁned  by  Asberg
et  al.  (1976)  and  Paykel  and  Rassaby  (1978):  non-violent  sui-
cid  attempts  include  drug  overdoses  and  single  wrists  cuts
or  a  combination  of  these.  All  other  attempts  were  classi-
ﬁed  as  violent  (e.g.  hanging,  drowning,  suffocating,  several
deep  cuts,  poisoning,  intentially  thowing  themselves  into
trafﬁc,  etc.)  (Asberg  et  al.,  1976;  Paykel  and  Rassaby,  1978).
All  study  participants  underwent  a  general  physical  exami-
nation,  which  showed  no  evidence  of  ongoing  infection  or
other  unknown  somatic  condition.
2.3.  Blood  sampling
Blood  samples  from  all  subjects  were  collected  between
7.30  and  8.00  in  the  morning,  after  a  night  of  fasting.  The
suicidal  patients  were  psychiatric  inpatients,  whereas  the
control-groups  had  spent  the  night  at  home.  Samples  from
all  study  participants  were  collected  within  a  week  from  the
physical  and  psychiatric  examination.  The  blood  was  placed
on  ice  and  centrifuged  (3000  r/min,  at  +4 ◦C)  within  an  hour.
Plasma  and  serum  were  stored  at  −80 ◦C  until  analysis.
Blood  samples  were  collected  from  all  seasons  throughout
the  year  for  the  suicidal  patients  and  from  all  seasons,
except  for  the  summer,  for  the  control  groups.  Blood  samples
from  healthy  controls  and  non-suicidal  depressed  patients
were  collected  between  2001  and  2003  and  from  suicide
attempters  between  2006  and  2008.
2.4.  Laboratory  analyses2.4.1.  25(OH)D2 and  25(OH)D3
Stored  serum  samples  were  thawed  and  analyzed  for
25(OH)D2,  and  25(OH)D3.  The  time  of  storage,  4—12  years  at
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80 ◦C,  is  not  likely  to  have  had  an  impact  on  the  quality  of
he  analysis  due  to  the  relatively  stable  vitamin  D  molecule
Wielders  and  Wijnberg,  2009;  Antoniucci  et  al.,  2005).  The
amples  had  not  been  thawed  prior  to  analyses.
Analyses  of  25(OH)D2 and  25(OH)D3 were  done  by  liquid-
hromatography-mass-spectrometry,  model  Sciex  API  4000
C/MS/MS  (MA,  USA).  Coefﬁcient  of  variation  (CV)  values
ere  as  follows:  for  25(OH)D2,  6,0%  at  40  nmol/L  and  5,0%  at
20  nmol/L  and  for  25(OH)D3 6,0%  at  40  nmol/L  and  4.0%  at
20  nmol/L.  The  Department  of  Clinical  Chemistry  at  Skåne
niversity  Hospital  is  accredited  by  SWEDAC  (the  Swedish
oard  for  Accreditation  and  Conformity  Assessment)  and
articipates  in  the  external  quality  assurance  program  of
EQAS  (Vitamin  D  External  Quality  Assessment  Scheme)
UK).
According  to  clinical  guidelines  (Phinney  et  al.,  2012),  in
ases  of  a  25(OH)D2 level  >10  nmol/L,  the  25(OH)D2 level
hould  be  added  to  the  25(OH)D3 level  and  accounted  for  as
5(OH)D3 in  the  statistical  analysis.  However,  no  patients  or
ontrols  in  this  study  had  a level  of  25(OH)D2 >  10  nmol/L  and
5(OH)D2 is  therefore  not  included  in  the  results  presented
ere.  The  serum  level  of  the  inactive  form  of  vitamin  D,
.e.  25(OH)D3,  is  referred  to  as  ‘vitamin  D’  throughout  the
rticle.  Its  active  form,  1.25(OH)2D3, is  referred  to  as  ‘active
itamin  D’.
.4.2.  Cytokines
L-6,  IL-1 and  TNF- were  measured  in  the  plasma
sing  ultra-sensitive  electrochemiluminescence  immunoas-
ays  according  to  the  manufacturer’s  recommendations
MesoScale  Discovery,  UK).  The  method  and  absolute  lev-
ls  of  the  cytokines  in  these  patients  have  been  published
Janelidze  et  al.,  2011).  In  the  current  paper  we  report
he  associations  of  the  cytokines  with  vitamin  D  levels.  All
amples  were  analyzed  in  duplicates.  The  detection  lim-
ts  for  IL-1, IL-6  and  TNF- were  0.014  pg/mL,  0.050  and
.075  pg/mL,  respectively.
.5.  Statistical  analyses
ll  statistical  analyses  were  performed  using  the  statisti-
al  package  SPSS  version  20  (SPSS  Inc.,  Illinois,  US).  For
ower  calculation,  mean  case  concentration  was  predicted
o  60  nmol/L  and  control  concentration  to  68  nmol/L  based
n  previous  literature  (Milaneschi  et  al.,  2014).  Standard
eviation  was  estimated  to  25  nmol/L.  The  computed  power
or  a  two-tailed  t-test  showed  that  87%  power  is  achieved
ith  n  =  59.  Vitamin  D  data  displayed  a  normal  distribution
nd  all  samples  were  above  detection  limit.  Data  for  the
ytokines  were  transformed  into  normal  distribution  using
he  natural  logarithms  before  statistical  analysis.  Samples
ith  zero  cytokine  levels  were  assigned  a  value  correspond-
ng  to  1/10  of  the  lowest  detectable  sample  in  the  assay.  This
pplied  to  six  samples  of  IL-1, three  from  the  non-suicidal
epressed  patients  and  three  from  the  healthy  controls.  IL-6
nd  TNF- had  one  sample  each  below  the  detection  range,
oth  occurring  among  the  healthy  controls.  The  potential
ffects  of  confounding  factors  were  tested  in  linear  regres-
ion  models.  Vitamin  D  was  found  to  be  associated  with  BMI
nd  age  of  the  subjects  and  therefore  all  analyses  were  per-
ormed  correcting  for  these  factors  using  linear  regression.
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For  normally  distributed  variables,  multiple  group-wise  com-
parisons  were  performed  using  One-way  ANOVAs  followed
by  Bonferroni-Dunn’s  post-hoc  tests.  Student’s  T-test  was
used  in  cases  when  only  two  groups  were  compared  (e.g.
violent  vs  non-violent  suicide  attempts).  Mann—Whitney  U
test  was  used  for  non-normally  distributed  variables  and
groups  of  heterogeneous  sizes.  Fishers  Exact  Test  was  used
for  comparing  proportions  of  patients  with  vitamin  D  deﬁ-
ciency  between  the  groups.  Correlations  between  cytokines
and  vitamin  D  were  assessed  using  Pearson’s  r.  The  alpha-
level  of  signiﬁcance  was  set  at  p  <  0.05.
3. Results
3.1.  Effects  of  age,  gender  and  BMI
Vitamin  D  correlated  signiﬁcantly  with  age  and  body  mass
index  (BMI)  (Pearson’s  r,  0.228  and  −0.276,  respectively,
p  <  0.05),  but  not  did  not  differ  between  gender  (Student’s
T-test,  ns).  All  subsequent  analyses  are  corrected  for  age
and  BMI.
3.2.  Vitamin  D  levels  are  lowest  in  suicidal  patients
The  suicide  attempters  had  signiﬁcantly  lower  mean  vita-
min  D  levels  than  the  non-suicidal  depressed  patients  and
the  healthy  controls  (One-Way  ANOVA,  Bonferroni  post-hoc
test,  p  < 0.05)  (Table  2,  Fig.  1).  The  mean  value  of  vitamin  D
among  the  suicide  attempters  was  47  ±  20  nmol/L  whereas
it  was  62  ±  27  nmol/L  among  the  depressed  non-suicidal
patients  and  65  ±  26  nmol/L  among  the  healthy  controls.
58%  of  the  suicide  attempters  in  this  study  were  found
to  have  deﬁcient  levels  of  vitamin  D  according  to  clinical
practice,  i.e.  below  50  nmol/L  (Holick,  2007;  Grober  et  al.,
2013).  The  percentages  of  patients  in  the  respective  group
with  vitamin  D  deﬁciency  are  listed  in  Table  2. The  group  of
suicidal  patients  contained  a  signiﬁcantly  greater  portion  of
individuals  with  suboptimal  or  deﬁcient  vitamin  D  levels  than
Table  2  Vitamin  D  mean  levels  and  percent  of  the  partici-
pants  below  different  vitamin  D  cut  off  levelsa.
Variable  Suicide
attempters
(n  =  59)
Non-
suicidal
depressed
patients
(n  =  17)
Healthy
controls
(n  =  14)
Vitamin  D
(mean  ±  SD),
nmol/L
47  ±  20  62  ±  27  65  ±  26
% <25  nmol/L
(10  ng/mL)
7%  12%  0%
% <50  nmol/L
(20  ng/mL)
58%  29%  29%
% <75  nmol/L
(30  ng/mL)
92%  59%  71%
a In clinical practice, the reference value for conﬁrmed vitamin
D deﬁciency is <50 nmol/L, and <25 nmol/L constitutes a severe
deﬁciency. Values below 75 nmol/L are considered suboptimal.
Fig.  1  Uncorrected  mean  vitamin  D  levels  for  the  three
studied groups.  The  signiﬁcant  differences  in  the  mean  vita-
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tin D  levels  between  the  suicidal  patients  and  the  healthy
ontrols/non-suicidal  depressed  patients  were  analyzed  statis-
ically using  a  variable  corrected  for  age  and  BMI  (*  p  <  0.05).
he  non-suicidal  depressed  patients  and  the  healthy  con-
rols  (Fisher’s  Exact  Test,  p  <  0.05  for  deﬁciency  and  p  <  0.01
or  suboptimal  levels).  No  signiﬁcant  difference  was  found
etween  the  groups  regarding  the  portions  having  a  severe
itamin  D  deﬁciency  (Fisher’s  Exact  test,  ns).
.3.  Seasonality
he  samples  from  the  suicide  attempters  were  collected
hroughout  all  four  seasons.  There  were  no  signiﬁcant  differ-
nces  in  the  levels  of  vitamin  D  between  samples  collected
n  winter,  fall,  spring  or  summer  (One-Way  ANOVA,  ns).  The
itamin  D  levels  were  lowest  in  winter,  but  this  did  not
each  statistical  signiﬁcance.  The  samples  from  the  healthy
ontrols  and  the  depressive  patients  were  collected  in  all
easons  except  for  the  summer,  whereas  seven  samples  from
uicide  attempters  were  collected  in  summer.  To  control  for
ny  potential  effect  of  sampling  season,  we  therefore  re-ran
he  group  comparisons  excluding  the  samples  from  suicide
ttempters  collected  in  the  summer.  This  did  not  affect  the
igniﬁcant  group  differences  reported.
.4.  Effects  of  endocrine  conditions  and
sychotropic  medications  on  vitamin  D  levels
ight  of  the  study  participants  had  an  endocrine  condition;
even  of  the  suicidal  patients  and  one  of  the  non-suicidal
epressed  patients  (Table  1).  Exclusion  of  these  eight  par-
icipants  did  not  affect  the  signiﬁcant  group  differences
eported.
Since  the  majority  of  suicidal  patients  were  on  psy-
hotropic  medication,  we  further  performed  a  linear
egression  with  vitamin  D  as  dependent,  and  age,  BMI
nd  the  major  psychotropic  medications  (neuroleptics,
erotonin-Norepinephrine  Reuptake  Inhibitor  (SNRI),  Selec-
ive  Serotonin  Reuptake  Inhibitor  (SSRI),  propiomazin  and
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Table  3  Vitamin  D  mean  levels  in  different  groupings  of
the suicidal  patients.
Groups  (n)  Vitamin  D  level
(mean  ±  SD)
(nmol/L)
Major  depressive  disorder  10  47  ±  18
Bipolar disorder  15  49  ±  19
Other psychiatric  illnessses  33  47  ±  22
aAffective  disorder  32  50  ±  20
bNon-affective  disorder  26  44  ±  20
Axis-II disorder 29  47  ±  22
No Axis-II  disorder 30  47  ±  19
Repeater 38  49  ±  21
Non-repeater  20  42  ±  19
Violent suicide  6  45  ±  19
Non-violent  suicide  52  47  ±  21
a The affective disorder group contains patients with major
depressive disorder (n = 10), bipolar I and II disorder (n = 15),
dysthymic disorder (n = 4) and depressive disorder NOS (n = 3).
b The non-affective disorder group contains patients with
schizoaffective disorder (n = 2), psychotic disorder NOS (n = 1),
anxiety disorder NOS (n = 4), generelized anxiety disorder (n = 1),
alcohol dependence (n = 6), substance dependence (n = 2),
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benzodiazepines)  as  independent  variables.  None  of  the
medications  had  any  signiﬁcant  effect  on  the  vitamin  D
levels  (n  =  49,  linear  regression,  ns).  Ten  of  the  suicide
attempters  were  treated  with  anti-epileptic  drugs.  No  sig-
niﬁcant  difference  in  the  mean  vitamin  D  levels  between
patients  who  took  anti-epileptic  drugs  and  patients  who  did
not  take  anti-epileptic  drugs  were  found  (Mann—Whitney  U
test,  ns).
3.5.  Relationship  of  vitamin  D  with  inﬂammatory
cytokines
There  was  a  negative  correlation  between  vitamin  D  and
IL-1  for  all  subjects  (n  =  68;  Pearson’s  r:  −0.240,  p  <  0.05).
There  were  no  signiﬁcant  correlations  between  vitamin  D
and  IL-6  and  TNF-alpha  in  all  subjects  (Pearson’s  r,  ns).
Individual  correlations  in  the  three  separate  groups
of  participants  showed  a  signiﬁcant  negative  correlation
between  vitamin  D  and  IL-1 in  the  group  of  suicide
attempters  (n  =  46;  Pearson’s  r:  −0.321,  p  <  0.05).  Vitamin
D  also  correlated  negatively  with  IL-6  in  the  group  of  non-
suicidal  depressed  patients  (n  =  17;  Pearson’s  r:  −0.582,
p  <  0.05).  No  other  associations  were  found  between  the
cytokines  and  vitamin  D  in  the  individual  groups.
3.6.  Vitamin  D,  psychiatric  diagnoses  and
suicidality
There  was  no  signiﬁcant  difference  between  vitamin  D  levels
in  the  three  main  groups  of  psychiatric  diagnosis,  i.e.  major
depressive  disorder  (n  =  10),  bipolar  disorder  (n  =  15)  and
other  psychiatric  illnesses  (n  =  28)  (One-Way  ANOVA,  ns)  or
between  those  with  an  affective  disorder  (n  =  31)  and  those
without  an  affective  disorder  (n  =  22)  (Mann—Whitney’s  U-
test,  ns).  Likewise,  there  was  no  signiﬁcant  difference
between  subjects  with  an  Axis-II  disorder  (n  =  27)  compared
to  those  without  (n  =  26)  (Student’s  T-test,  ns).  The  levels  of
vitamin  D  and  the  details  of  the  respective  groups  are  shown
in  Table  3.
We  also  analyzed  different  aspects  of  suicidality  by  com-
paring  suicide  attempt  repeaters  (n  =  35)  to  non  repeaters
(n  =  17);  and  those  who  had  committed  a  violent  suicide
attempt  (n  =  6)  to  those  who  had  committed  a  non-violent
suicide  attempt  (n  =  46)  but  there  were  no  signiﬁcant  differ-
ences  between  these  groups  (Mann—Whitney’s  U-test,  ns)
(Table  3).
4. Discussion
We  found  that  suicidal  patients  had  signiﬁcantly  lower
mean  levels  of  vitamin  D  than  both  non-suicidal  depressive
patients  and  healthy  controls.  58%  of  the  suicidal  patients
were  clinically  deﬁcient  in  vitamin  D,  compared  to  around
30%  in  the  healthy  controls  and  the  non-suicidal  depressed
patients.  Interestingly,  there  was  a  negative  association
between  the  blood  levels  of  vitamin  D  and  pro-inﬂammatory
cytokine  levels  in  the  psychiatric  patients.  Thus,  the  lower
the  vitamin  D,  the  higher  the  levels  of  the  key  inﬂammatory
cytokines  IL-6  and  IL-1 in  the  blood.  The  design  of  this  study
focused  on  suicidality  as  a  cross-diagnostic  phenomenon,
i
a
a
fadjustment disorder (n = 7) and adjustment disorders with
depressed mood (n = 3).
nrolling  patients  based  on  a  suicide  attempt,  irrespective
f  underlying  psychiatric  diagnosis.  Our  hypothesis  was  that
e  would  ﬁnd  signiﬁcant  biological  changes  associated  with
uicidality.  Indeed,  in  this  study  we  found  that  the  suicide
ttempters  had  signiﬁcantly  lower  vitamin  D  levels  than
oth  the  non-suicidal  depressive  patients  and  the  healthy
ontrols.  In  a previous  study,  we  found  similar  results  for  ele-
ations  of  pro-inﬂammatory  cytokines,  where  IL-6  and  TNF-
ere  increased  in  the  suicidal  patients,  but  not  in  non-
uicidal  depressive  and  healthy  controls  (Janelidze  et  al.,
011).  Therefore,  our  results  indicate  that  these  biological
lterations  might  indeed  be  speciﬁc,  or  most  pronounced
n  suicidal  patients.  To  further  analyze  whether  the  vita-
in  D  levels  differed  between  diagnostic  groups,  we  here
ompared  the  levels  between  patients  with  and  without
ersonality  disorders  as  well  as  the  main  Axis-I  diagnoses
mong  the  suicide  attempters,  but  we  did  not  detect  any  sig-
iﬁcant  differences  related  to  suicidality  apart  from  those
escribed  above.  In  the  future,  it  will  be  of  interest  to
ompare  the  vitamin  D  levels  between  other  groups  of  psy-
hiatric  patients.
The  cross-sectional  design  of  this  study  does  not  allow
ny  conclusions  regarding  whether  vitamin  D  is  a  direct
iological  cause  of  psychiatric  illness  or  suicidal  behav-
or.  However,  there  are  several  ways  by  which  vitamin  D
ould  affect  the  brain.  For  example,  vitamin  D  receptors
VDRs)  and  the  vitamin  D  activating  enzyme  1-hydroxylase
1OHase)  are  widely  spread  in  the  adult  human  brain,  sug-
esting  an  autocrine/paracrine  function  of  vitamin  D  (Eyles
t  al.,  2005).  Both  VDRs  and  1OHase  have  been  identiﬁed
n  neurons  and  microglial  cells,  the  primary  mediators  of
 pro-inﬂammatory  immune  response  in  the  brain  (McCann
nd  Ames,  2008).  Brain  areas  with  abundant  VDRs  are  Pre-
rontal  cortex,  Cingulate  gyrus,  Hippocampus  (especially
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A1  and  CA2),  Substantia  Nigra  and  Hypothalamus.  Vitamin
 has  been  proposed  to  act  like  other  neurosteroids  and
lay  a  role  in  maintaining  normal  brain  function  by  mod-
lating  neuronal  excitability,  regulating  the  production  of
peciﬁc  neurotrophins  and  by  having  neuroprotective  effects
Eyles  et  al.,  2005;  Harms  et  al.,  2011).  Animal  models  have
hown  that  active  vitamin  D  also  increases  the  ﬁrst  and
ate-limiting  enzyme,  tyrosine  hydroxylase  (TH),  in  the  cat-
cholamine  biosynthetic  pathway,  and  thus  may  contribute
o  responses  and  adaptation  to  stress,  arousal,  mood  and
otivated  behavior  (Puchacz  et  al.,  1996).
Vitamin  D  is  also  known  to  exert  profound  immune  mod-
lating  effects  by  increasing  the  levels  of  anti-inﬂammatory
ytokines  such  as  IL-10,  IL-4,  IL-5  and  transforming
rowth  factor  (TGF)-, and  by  decreasing  pro-inﬂammatory
ytokines  IL-1, IL-2,  IL-6,  INF-, TNF- and  IL-12  (Baeke
t  al.,  2010;  Zhang  et  al.,  2012a).  The  net  result  of  these
ffects  is  a  shift  from  a  Th1  to  a  Th2  immunological  phe-
otype,  which  is  considered  to  be  a  less  pro-inﬂammatory
tate  (Borges  et  al.,  2011).  As  we  and  others  have  previously
ound  pro-inﬂammatory  cytokines  to  be  increased  in  suicidal
atients  (Lindqvist  et  al.,  2009;  Janelidze  et  al.,  2011),  our
ypothesis  was  that  a  deﬁciency  in  vitamin  D  could  be  part  of
he  pathology  underlying  these  changes.  Indeed,  because  we
ere  found  that  low  vitamin  D  levels  were  signiﬁcantly  asso-
iated  with  higher  levels  of  the  pro-inﬂammatory  cytokines
n  plasma  of  the  psychiatric  patients,  the  data  is  in  line  with
ur  primary  hypothesis.
Another  way  in  which  vitamin  D  could  be  a  contributing
actor  to  suicidality  is  its  impact  on  the  serotonin  levels.  Low
erotonin  levels  have,  for  example,  been  associated  with
ggressive  suicide  attempts  and  impulsive  behavior,  charac-
eristic  for  suicidal  patients  (Sadkowski  et  al.,  2013).  Active
itamin  D  has  been  shown  to  activate  the  transcription  of
he  serotonin-synthesizing  gene,  tryptophan  hydroxylase  2
TPH2),  in  the  brain  (Patrick  and  Ames,  2014).  Active  vita-
in  D  has  also  been  shown  to  increase  p11  (also  known  as
100A10),  a  protein  which  interacts  with  and  transports  the
-hydroxytryptamine  (5-HT)1B receptor  (serotonin  receptor)
rom  the  cytoplasm  to  the  membrane  (van  de  Graaf  et  al.,
003;  Zhang  et  al.,  2011).  A  recent  study  demonstated  that
11  mRNA  expression  levels  are  lower  in  the  stress-related
rain  regions  of  suicide  victims  (Anisman  et  al.,  2008).
A  deﬁciency  in  vitamin  D  is  deﬁned  as  blood  levels  of
ess  than  50  nmol/L,  while  levels  below  25  nmol/L  are  con-
idered  to  constitute  a  severe  deﬁciency.  Vitamin  D  levels
etween  100  and  150  nmol/L  are  considered  ideal,  but  lev-
ls  above  75  nmol/L  are  generally  thought  to  be  sufﬁcient
Holick,  2007;  Grober  et  al.,  2013).  While  most  of  the  rec-
mmendations  concerning  the  clinical  reference  interval  for
itamin  D  are  based  on  skeletal  health,  the  effects  on  other
iological  systems  are  less  characterized,  and  it  is  possible
hat  different  vitamin  D  levels  are  optimal  in  different  tis-
ues.  Vitamin  D  suppresses  lipopolysaccharide  (LPS)-induced
L-6  and  TNF- production  by  human  monocytes  in  culture
t  vitamin  D  levels  of  75  nmol/L,  but  not  at  37.5  nmol/L.  It
s  therefore  proposed  that  patients  with  chronic  inﬂamma-
ory  diseases,  deﬁcient  in  vitamin  D,  should  beneﬁt  from
itamin  D  supplementation  up  to  a  serum  level  of  above
5  nmol/L  (Zhang  et  al.,  2012a).  Multiple  sclerosis  (MS)  has
lso  been  linked  to  vitamin  D  deﬁciency.  In  an  animal  model
f  MS,  experimental  autoimmune  encephalomyelitis  (EAE),
t
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itamin  D  status  determines  the  severity  of  the  disease
Cantorna,  2000;  Ascherio  et  al.,  2014).  Thus,  supplemen-
ation  with  active  vitamin  D  blocks  EAE-progression  whereas
itamin  D  deﬁciency  accelerates  the  EAE  onset.  Recent  clin-
cal  guidelines  now  recommend  that  patients  with  MS  who
re  deﬁcient  in  vitamin  D  should  receive  supplement  of  the
itamin  when  their  blood  levels  are  below  75  nmol/L  (Brum
t  al.,  2014).  Interestingly,  in  our  current  study  as  many  as
90%  of  the  suicide  attempters  had  suboptimal  vitamin  D
evels  (below  75  nmol/L),  and  could  thus  be  candidates  for
itamin  D  treatment  in  future  trials.  Thus,  we  argue  that
outine  clinical  testing  of  vitamin  D  levels  could  be  beneﬁcial
n  psychiatric  patients  (speciﬁcally  in  patients  with  suicidal
ymptoms),  with  subsequent  supplementation  in  patients
hat  are  found  to  be  deﬁcient,  or  with  suboptimal  levels.
Why  were  the  subjects  in  our  study  deﬁcient  in  vitamin  D?
lthough  the  study  did  not  aim  to  characterize  the  underly-
ng  cause  of  vitamin  deﬁciency,  we  were  able  to  examine  the
ffects  of  some  potential  confounders.  Well-established  risk
actors  for  vitamin  D  deﬁciency  are  high  age,  obesity,  liver
r  kidney  disease  and  low  exposure  to  sunlight.  In  our  study,
ll  results  were  corrected  for  effects  of  age  and  BMI.  None  of
he  study  participants  had  any  liver  or  kidney  disease.  How-
ver,  a limitation  of  the  study  is  that  we  do  not  have  any
etailed  data  regarding  the  ethnicity  of  the  participants,
lthough  the  large  majority  of  the  patients  at  Lund’s  Univer-
ity  Hospital  are  of  Swedish  origin  with  a  Caucasian  ethnicity.
e  also  lack  data  regarding  smoking  habits  among  the  partic-
pants,  which  is  a  potential  confounder  that  could  inﬂuence
ytokine  levels  and  possibly  also  vitamin  D  levels  (Brot  et  al.,
999;  Shirazi  et  al.,  2013).  Another  potential  confounder  is
he  inﬂuence  of  sun  exposure.  As  the  major  source  of  vitamin
 production  is  the  skin,  vitamin  D  status  can  be  considered  a
urrogate  marker  of  sunlight  exposure.  It  has  been  demon-
trated,  in  vitro  and  in  vivo,  that  UV-light  mediates  both
nﬂammatory  and  immunosuppresive  effects  that  may  be  at
east  partially  distinct  from  those  exerted  directly  by  vita-
in  D  (Norval  and  Halliday,  2011;  Li  et  al.,  2013).  Clinical
tudies  investigating  the  effects  of  UV-therapy  on  depressive
nd  suicidal  patients  are  therefore  warranted  independently
f  studies  aimed  solely  at  restoring  vitamin  D  levels.  We  do
ot  have  any  data  about  the  sun  exposure  of  the  study  par-
icipants  prior  to  the  study  and  can  therefore  not  adjust  our
esults  for  this  confounder,  although  we  could  conclude  that
easonality  did  not  impact  the  group  differences.
There  is  currently  insufﬁcient  knowledge  about  the
ffects  of  different  pharmacological  agents  on  vitamin  D.
ccording  to  a  recent  review  there  is  insufﬁcient  evidence
o  determine  whether  medications  that  have  previously
een  suggested  to  alter  vitamin  D  levels  actually  do  have
his  effect  (Robien  et  al.,  2013).  It  is  well  known,  though,
hat  osteomalacia  is  a serious  side  effect  from  certain  drug
herapies.  Chronic  administration  of  anti-epileptic  drugs
nd  treatment  with  the  antimicrobial  drug  rifampin  have
hown  the  strongest  association  with  osteomalacia.  The
xact  mechanism  underlying  this  association  is  yet  not  fully
nderstood,  but  lowered  vitamin  D  levels  is  one  of  the  pro-
osed  mechanisms  (Wang  et  al.,  2013).  In  our  study,  none  of
he  major  pharmacological  groups  of  agents  had  any  signif-
cant  effects  on  the  levels  of  vitamin  D.  Ten  of  the  suicide
ttempters  were  treated  with  anti-epileptic  drugs,  although
here  were  no  signiﬁcant  difference  in  the  mean  vitamin  D
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levels  between  them  and  the  patients  who  did  not  take  anti-
epileptic  drugs.  We  therefore  do  not  interpret  our  data  as
resulting  from  any  medications  used  by  the  patients.
5. Conclusions
In  summary,  we  found  that  58%  of  the  suicide  attempters
in  our  study  suffered  from  vitamin  D  deﬁciency,  and  that
their  levels  of  vitamin  D  were  signiﬁcantly  lower  than  those
in  healthy  controls  and  depressive  patients  without  suici-
dality.  Interestingly,  the  low  levels  of  vitamin  D  in  plasma
were  associated  with  elevated  inﬂammatory  markers  in  the
psychiatric  patients  (speciﬁcally  IL-1 and  IL-6).  As  we  and
others  have  previously  shown  that  peripheral  and  central
inﬂammation  is  increased  in  suicidal  patients,  we  here  sug-
gest  that  low  levels  of  vitamin  D  could  be  a  contributing
cause  of  this  inﬂammation.  As  inﬂammation  is  suggested
to  directly  be  part  of  the  neural  mechanisms  underlying
depressive  and  suicidal  behavior,  it  should  be  of  high  rel-
evance  to  detect  and  cure  the  vitamin  D  deﬁciency  in  these
patients.  As  blood  tests  for  vitamin  D  levels  can  be  readily
done,  as  well  as  substitution  with  vitamin  D,  this  could  be
implicated  in  clinical  practice  within  a  short  time-frame.
To  determine  whether  vitamin  D  substitution  decreases  sys-
temic  inﬂammation  and  improves  depressive  and  suicidal
symptoms,  clinical  trials  are  highly  warranted.
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